Molecular progression of chronic rhinosinusitis: a pseudotime reconstruction of a transcriptomic dataset
Main Article Content
Abstract
Background
Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease that is classified based on the presence of nasal polyps. However, whether CRS and nasal polyps represent discrete entities or a continuous progression remains unclear. Most studies have relied on cross-sectional comparisons, which limit insight into its pathophysiology. This study aimed to test whether CRS subtypes lie on a continuous trajectory by applying pseudotime ordering to CRS transcriptomic data.
Methods
Gene expression data were obtained from the Gene Expression Omnibus (GSE36830), which consists of control, chronic rhinosinusitis without nasal polyps (CRSsNP), uncinate tissue (CRSwNP UT), and nasal polyp tissue (CRSwNP NP) from chronic rhinosinusitis with nasal polyps. Pathway activity was quantified using Gene Set Variation Analysis (GSVA) based on gene sets for immune, inflammatory, and epithelial pathways. Highly variable pathways were selected and used as input to reconstruct a pseudotemporal disease trajectory. Statistical associations were assessed using Spearman correlation and the Jonckheere–Terpstra trend test.
Results
Pseudotime reconstruction showed an ordered molecular trajectory extending from control samples through CRSsNP and CRSwNP UT, with nasal polyp samples forming a distinct end stage. Pseudotime showed a strong monotonic association with disease stage (Spearman's ρ=0.743, p<0.001), indicating an ordered progression of molecular changes across disease states. Progressive disease was characterized by increasing activation of immune pathways, including hypersensitivity, alongside declining activity of epithelial stress response and metabolic pathways.
Conclusion
These findings demonstrate that CRS represents a continuous molecular disease spectrum. Nasal polyposis emerges as a distinct molecular end state characterized by dominant immune activation. This pseudotime-based framework provides insight into CRS pathogenesis and provides evidence for specific therapeutic strategies.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
1. Chin CJ, Scott JR, Lee JM. Diagnosis and management of chronic rhinosinusitis. Can Med Assoc J 2025;197:E148–54. doi:10.1503/cmaj.241101.
2. Hirsch AG, Stewart WF, Sundaresan AS, et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy 2017;72:274–81. doi:10.1111/all.13042.
3. Toppila-Salmi S, Bjermer L, Cardell LO, et al. Multi-disciplinary expert perspective on the management of type 2 inflammation-driven severe CRSwNP: a brief overview of pathophysiology and recent clinical insights. J Asthma Allergy 2024;17:431–9. doi:10.2147/JAA.S447093.
4. Elboraei Y, Aqeel J Alanazi D, Saud J Alanazi R, et al. A contemporary review of chronic rhinosinusitis: pathophysiology, diagnosis, and evolving treatment strategies. J Pioneer Med Sci 2025;14:100–9. doi:10.47310/jpms2025140813.
5. Vlaminck S, Acke F, Scadding GK, Lambrecht BN, Gevaert P. Pathophysiological and clinical aspects of chronic rhinosinusitis: current concepts. Front Allergy 2021;2:741788. doi:10.3389/falgy.2021.741788.
6. Cho SH, Kim DW, Gevaert P. Chronic rhinosinusitis without nasal polyps. J Allergy Clin Immunol Pract 2016;4:575–82. doi:10.1016/j.jaip.2016.04.015.
7. Min HK, Lee S, Kim S, et al. Global incidence and prevalence of chronic rhinosinusitis: a systematic review. Clin Exp Allergy 2025;55:52–66. doi:10.1111/cea.14592.
8. Peters AT, Rolland C, Lavoie L, Fung S, Basoff D, Chitnis A. The burden of chronic rhinosinusitis without nasal polyps: a systematic review of epidemiological, clinical, humanistic, and economic evidence. Adv Ther 2026. doi:10.1007/s12325-026-03575-7. Online ahead of print.
9. DeConde AS, Soler ZM. Chronic rhinosinusitis: epidemiology and burden of disease. Am J Rhinol Allergy 2016;30:134–9. doi:10.2500/ajra.2016.30.4297.
10. Wang M, Li Y, Li J, et al. New insights into the endotypes of chronic rhinosinusitis in the biologic era. J Allergy Clin Immunol 2025;156:51–60. doi:10.1016/j.jaci.2025.02.015
11. Cui N, Zhu X, Zhao C, Meng C, Sha J, Zhu D. A decade of pathogenesis advances in non-type 2 inflammatory endotypes in chronic rhinosinusitis: 2012–2022. Int Arch Allergy Immunol 2023;184:1237–53. doi:10.1159/000532067.
12. Sundaresan AS, Hirsch AG, Storm M, et al. Occupational and environmental risk factors for chronic rhinosinusitis: a systematic review. Int Forum Allergy Rhinol 2015;5:996–1003. doi:10.1002/alr.21573.
13. Book R, Lazutkin A, Eliashar R. Long-term real-world outcomes and insights of biologic therapies in chronic rhinosinusitis with nasal polyps. Int J Mol Sci 2025;26:4694. doi:10.3390/ijms26104694.
14. Chiu J, Fastenberg J, Tong C, Navetta‐Modrov B, Marcus S. Biologics for chronic rhinosinusitis with nasal polyposis: current landscape and future directions. Laryngoscope Investig Otolaryngol 2025;10: e70282. doi:10.1002/lio2.70282.
15. Huber P, Förster‐Ruhrmann U, Olze H, et al. Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years. Allergy 2024;79:3108–17. doi:10.1111/all.16263.
16. Bolk KG, Wise SK. Biologic therapies across nasal polyp subtypes. J Pers Med 2024;14:432. doi:10.3390/jpm14040432.
17. Yang C, Guo L, Wang Y, Jiang W, Chen S, Gu Q. The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis. Front Allergy 2025;6:1599797. doi:10.3389/falgy.2025.1599797.
18. Bachert C, Desrosiers M, Mullol J, et al. A randomized phase 3 study, Sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2019;143:AB433. doi:10.1016/j.jaci.2018.12.980.
19. Toppila‐Salmi S, Reitsma S, Hox V, et al. Endotyping in chronic rhinosinusitis—an EAACI task force report. Allergy 2025;80:132–47. doi:10.1111/all.16418.
20. Cho SH, Hamilos DL, Han DH, Laidlaw TM. Phenotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract 2020;8:1505–11. doi:10.1016/j.jaip.2019.12.021.
21. Wang Y, Song X, Jin M, Lu J. Characterization of the immune microenvironment and identification of biomarkers in chronic rhinosinusitis with nasal polyps using single-cell RNA sequencing and transcriptome analysis. J Inflamm Res 2024;17:253–77. doi:10.2147/JIR.S440409.
22. Wang Y, Li Z, Lu J. Single-cell RNA sequencing reveals the epithelial cell, fibroblast, and key gene alterations in chronic rhinosinusitis with nasal polyps. Sci Rep 2024;14:2270. doi:10.1038/s41598-024-52341-8.
23. Jin Y, Liang Y, Wang Z, Jiang Y, Yuan F, Zhang T. Single cell transcriptomic analysis reveals transcriptome differences of different cells between eosinophilic chronic rhinosinusitis with nasal polyps and non-eosinophilic chronic rhinosinusitis with nasal polyps. PLoS One 2025;20:e0328241. doi:10.1371/journal.pone.0328241.
24. Staudacher AG, Peters AT, Kato A, Stevens WW. Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis. Ann Allergy Asthma Immunol 2020;124:318–25. doi:10.1016/j.anai.2020.01.013.
25. Gleason BN, Luo Z, Agarwal A, et al. Factor analysis‐based quantitative endotyping improves associations with CRS cross‐sectional and longitudinal outcomes. Int Forum Allergy Rhinol 2026;16:32–42. doi:10.1002/alr.70027.
26. Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis: role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med 2015;192:682–94. doi:10.1164/rccm.201412-2278OC.
27. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175–91. doi:10.3758/BF03193146.
28. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27:1739–40. doi:10.1093/bioinformatics/btr260.
29. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst 2015;1:417–25. doi:10.1016/j.cels.2015.12.004
30. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 2013;14:7. doi:10.1186/1471-2105-14-7.
31. Succar EF, Turner JH. Recent advances in understanding chronic rhinosinusitis endotypes. F1000Res 2018;7:1909. doi:10.12688/f1000research.16222.1.
32. Abuduruk SH, Sabb Gul BK, Al Masoudi SM, et al. Factors contributing to the recurrence of chronic rhinosinusitis with nasal polyps after endoscopic sinus surgery: a systematic review. Cureus 2024;16:e67910. doi:10.7759/cureus.67910.
33. Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol 2022;149:1491–503. doi:10.1016/j.jaci.2022.02.016.
34. Li M, Xie Y, Zhao K, et al. Endoplasmic reticulum stress exacerbates inflammation in chronic rhinosinusitis with nasal polyps via the transcription factor XBP1. Clin Immunol 2021;223:108659. doi:10.1016/j.clim.2020.108659.
35. Guo S, Tian M, Fan Y, Zhang X. Recent advances in mass spectrometry-based proteomics and metabolomics in chronic rhinosinusitis with nasal polyps. Front Immunol 2023;14:1267194. doi:10.3389/fimmu.2023.1267194.
36. He Y, Fu Y, Wu Y, Zhu T, Li H. Pathogenesis and treatment of chronic rhinosinusitis from the perspectiveof sinonasal epithelial dysfunction. Front Med (Lausanne) 2023;10:1139240. doi:10.3389/fmed.2023.1139240.
37. Kucuksezer UC, Ozdemir C, Yazici D, et al. The epithelial barrier theory: development and exacerbation of allergic and other chronic inflammatory diseases. Asia Pac Allergy 2023;13:28–39. doi:10.5415/apallergy.0000000000000005.
38. Zhipu N, Zitao H, Jichao S, Cuida M. Research advances in roles of microRNAs in nasal polyp. Front Genet 2022;13:1043888. doi:10.3389/fgene.2022.1043888.
39. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020;146:595–605. doi:10.1016/j.jaci.2020.05.032.
40. Ha JG, Cho HJ. Unraveling the role of epithelial cells in the development of chronic rhinosinusitis. Int J Mol Sci 2023;24:14229. doi:10.3390/ijms241814229.